[go: up one dir, main page]

BE2011C041I2 - - Google Patents

Download PDF

Info

Publication number
BE2011C041I2
BE2011C041I2 BE2011C041C BE2011C041C BE2011C041I2 BE 2011C041 I2 BE2011C041 I2 BE 2011C041I2 BE 2011C041 C BE2011C041 C BE 2011C041C BE 2011C041 C BE2011C041 C BE 2011C041C BE 2011C041 I2 BE2011C041 I2 BE 2011C041I2
Authority
BE
Belgium
Application number
BE2011C041C
Other languages
French (fr)
Original Assignee
Bristol-Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co filed Critical Bristol-Myers Squibb Co
Publication of BE2011C041I2 publication Critical patent/BE2011C041I2/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE2011C041C 2000-05-26 2011-11-10 BE2011C041I2 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (1)

Publication Number Publication Date
BE2011C041I2 true BE2011C041I2 (zh) 2020-08-20

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2011C041C BE2011C041I2 (zh) 2000-05-26 2011-11-10

Country Status (41)

Country Link
EP (3) EP1248802B9 (zh)
JP (1) JP4328525B2 (zh)
KR (2) KR100895134B1 (zh)
CN (2) CN1309735C (zh)
AR (1) AR031699A1 (zh)
AT (1) ATE271066T1 (zh)
AU (2) AU6346601A (zh)
BE (1) BE2011C041I2 (zh)
BR (1) BRPI0111191B8 (zh)
CA (1) CA2409748C (zh)
CY (2) CY2011019I1 (zh)
CZ (1) CZ304451B6 (zh)
DE (2) DE60104282T2 (zh)
DK (1) DK1248802T3 (zh)
EC (1) ECSP024365A (zh)
EE (2) EE05458B1 (zh)
EG (1) EG24459A (zh)
ES (2) ES2571852T3 (zh)
FR (1) FR11C0053I2 (zh)
GE (1) GEP20053658B (zh)
HK (1) HK1048126B (zh)
HU (2) HU228137B1 (zh)
IL (1) IL152315A (zh)
LT (1) LT5133B (zh)
LU (1) LU91902I2 (zh)
LV (1) LV12994B (zh)
MX (1) MXPA02011534A (zh)
MY (1) MY136113A (zh)
NO (2) NO330797B1 (zh)
PE (1) PE20011338A1 (zh)
PL (1) PL206267B1 (zh)
PT (1) PT1248802E (zh)
RU (1) RU2283847C2 (zh)
SI (1) SI1248802T1 (zh)
SK (1) SK288131B6 (zh)
TR (1) TR200402703T4 (zh)
TW (2) TWI314933B (zh)
UA (1) UA87432C2 (zh)
UY (1) UY26723A1 (zh)
WO (1) WO2001092337A2 (zh)
ZA (1) ZA200208944B (zh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
AR035037A1 (es) * 2000-07-03 2004-04-14 Bristol Myers Squibb Co Metodos para tratar enfermedades reumaticas al usar una molecula ctla4 soluble
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
AU2003243152A1 (en) * 2002-04-19 2003-11-03 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
PL377603A1 (pl) * 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Poprawa jakości produktu w hodowlach komórek ssaczych do wytwarzania białka
CN101044239B (zh) 2002-12-23 2010-12-08 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
CA2511823A1 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
AU2004287431B2 (en) 2003-10-27 2010-03-11 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
ES2439641T3 (es) 2005-12-20 2014-01-24 Bristol-Myers Squibb Company Composiciones y procedimientos de producción de una composición
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
WO2008076487A2 (en) 2006-12-20 2008-06-26 Verenium Corporation Antibodies and methods for making and using them
WO2009058564A2 (en) * 2007-11-01 2009-05-07 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids
KR20190064664A (ko) * 2008-10-02 2019-06-10 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Ｃｄ86 길항제 다중-표적 결합 단백질
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
ES2550060T3 (es) 2010-03-12 2015-11-04 Abbvie Biotherapeutics Inc. Proteínas de CTLA4 y sus usos
EP2678423A1 (en) 2011-02-23 2014-01-01 Amgen Inc. Cell culture media for uvc exposure and methods related thereto
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
MX355234B (es) * 2012-05-11 2018-04-11 Medimmune Ltd Variantes de antigeno 4 del linfocito t citotoxico (ctla-4).
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
CA2877986A1 (en) * 2012-06-27 2014-01-03 Orban Biotech Llc Ctla4 fusion proteins for the treatment of diabetes
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
BR112016015797B1 (pt) 2014-01-13 2022-10-11 Amgen Inc Método para diminuir o teor de glicoforma de alta manose de uma proteína recombinante e método de produção de uma proteína recombinante
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
FI3926051T3 (fi) 2014-06-04 2024-06-18 Amgen Inc Menetelmiä nisäkässoluviljelmien keräämiseksi
AU2015355087B2 (en) 2014-12-01 2020-04-09 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
KR20240046641A (ko) 2015-04-17 2024-04-09 알파인 이뮨 사이언시즈, 인코포레이티드 조율가능한 친화성을 갖는 면역조절 단백질
CA2997947A1 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
JP2018536404A (ja) 2015-11-09 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法
WO2018053506A1 (en) * 2016-09-19 2018-03-22 Oncoimmune, Inc. Cd80 and cd86 binding protein compositions and uses thereof
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
CN116555353A (zh) 2017-04-20 2023-08-08 E开创生物技术股份有限公司 产生基因修改的动物的方法
KR102758545B1 (ko) 2017-10-10 2025-01-23 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
US12297253B2 (en) 2018-01-03 2025-05-13 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
CN115551530A (zh) 2019-08-27 2022-12-30 通尼克斯制药有限公司 经修饰的tff2多肽
WO2021112926A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
US12103960B2 (en) 2020-05-08 2024-10-01 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
MX2022016104A (es) 2020-06-18 2023-02-01 Regeneron Pharma Enfoque de peptidos pesados para medir con precision lisina de extremo c-terminal sin procesar.
WO2022027013A1 (en) 2020-07-28 2022-02-03 Seagen Inc. Methods and systems for producing polypeptides
EP4448022A2 (en) 2021-12-16 2024-10-23 Bristol-Myers Squibb Company Detergent for viral inactivation
KR20240167716A (ko) 2022-03-02 2024-11-27 리제너론 파아마슈티컬스, 인크. 고역가 항체의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ES2123001T5 (es) * 1991-06-27 2009-04-16 Bristol-Myers Squibb Company Receptor ctl4a, proteinas de fusion que lo contienen y sus usos.
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
EP1119253A4 (en) * 1998-10-07 2005-12-21 Millennium Pharm Inc NEW SPECIFIC MOLECULES OF Th2 AND USES THEREOF
AR035037A1 (es) * 2000-07-03 2004-04-14 Bristol Myers Squibb Co Metodos para tratar enfermedades reumaticas al usar una molecula ctla4 soluble

Also Published As

Publication number Publication date
AR031699A1 (es) 2003-10-01
MY136113A (en) 2008-08-29
WO2001092337A2 (en) 2001-12-06
SI1248802T1 (en) 2005-02-28
CY2011019I2 (el) 2016-12-14
KR20030009502A (ko) 2003-01-29
NO20025656L (no) 2002-11-25
CY2011019I1 (el) 2016-12-14
AU2001263466C1 (en) 2006-10-26
KR100889887B1 (ko) 2009-03-24
BRPI0111191B1 (pt) 2019-12-31
MXPA02011534A (es) 2004-08-12
ECSP024365A (es) 2003-03-31
EE05458B1 (et) 2011-08-15
CA2409748A1 (en) 2001-12-06
JP2004511213A (ja) 2004-04-15
HUP0302201A3 (en) 2010-01-28
ATE271066T1 (de) 2004-07-15
DE122011100063I1 (de) 2012-06-14
NO2011027I2 (zh) 2011-12-15
DE60104282T2 (de) 2005-10-13
EP1248802B1 (en) 2004-07-14
LV12994B (en) 2003-08-20
HUS1300012I1 (hu) 2016-08-29
IL152315A (en) 2010-04-15
TWI319405B (en) 2010-01-11
ES2225549T3 (es) 2005-03-16
EP1248802B9 (en) 2005-05-11
PT1248802E (pt) 2004-11-30
BRPI0111191B8 (pt) 2021-05-25
FR11C0053I2 (fr) 2013-01-11
AU6346601A (en) 2001-12-11
EE200200659A (et) 2004-06-15
NO330797B1 (no) 2011-07-18
ES2571852T3 (es) 2016-05-27
TW200906857A (en) 2009-02-16
CZ304451B6 (cs) 2014-05-14
PL206267B1 (pl) 2010-07-30
KR100895134B1 (ko) 2009-05-04
HK1048126B (zh) 2005-03-04
EP3029062A1 (en) 2016-06-08
CN1441810A (zh) 2003-09-10
CA2409748C (en) 2008-09-16
SK288131B6 (sk) 2013-10-02
NO20025656D0 (no) 2002-11-25
PE20011338A1 (es) 2002-01-13
TR200402703T4 (tr) 2004-11-22
BR0111191A (pt) 2004-07-06
HK1071931A1 (zh) 2005-08-05
SK15702002A3 (sk) 2004-01-08
RU2283847C2 (ru) 2006-09-20
EE201100050A (et) 2011-10-17
NO2011027I1 (no) 2012-01-09
PL366231A1 (en) 2005-01-24
GEP20053658B (en) 2005-11-10
CY1117625T1 (el) 2017-04-26
EP1248802A2 (en) 2002-10-16
AU2001263466B2 (en) 2006-04-27
LT2002114A (en) 2003-12-29
LT5133B (lt) 2004-05-25
EE05557B1 (et) 2012-08-15
JP4328525B2 (ja) 2009-09-09
UA87432C2 (uk) 2009-07-27
HU228137B1 (en) 2012-12-28
ZA200208944B (en) 2004-02-13
EP1536234A3 (en) 2009-06-03
FR11C0053I1 (zh) 2012-01-13
EG24459A (en) 2009-07-16
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
DK1248802T3 (da) 2004-11-15
CZ20023892A3 (cs) 2003-09-17
EP1536234B1 (en) 2016-03-16
IL152315A0 (en) 2003-05-29
HUP0302201A2 (hu) 2003-10-28
EP1536234A2 (en) 2005-06-01
UY26723A1 (es) 2001-12-28
TWI314933B (en) 2009-09-21
CN101255192A (zh) 2008-09-03
HK1048126A1 (zh) 2003-03-21
DE60104282D1 (de) 2004-08-19
CN1309735C (zh) 2007-04-11
WO2001092337A3 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
BE2017C009I2 (zh)
BE2016C059I2 (zh)
BE2014C035I2 (zh)
BRPI0113085B8 (zh)
JP2000280854A5 (zh)
CH694022C1 (zh)
CN300955183S (zh) 连接件
ECSDI000616S (zh)
CN3134543S (zh)
CN3139848S (zh)
AU2000280296A8 (zh)
AU2000280319A8 (zh)
AU2000276986A8 (zh)
AU2000276891A8 (zh)
AU2000276780A8 (zh)
AU2000266391A8 (zh)
AU2000264849A8 (zh)
BY6855C1 (zh)
AU2000256911A8 (zh)
CL2001002979A1 (zh)
AU2000256695A8 (zh)
CN3133324S (zh)
AU2000239526A8 (zh)
CN3134893S (zh)
CN3135513S (zh)